ASILOMAR, California – April 20, 2015 – At the 56th Experimental Nuclear Magnetic Resonance Conference (www.enc-conference.org), Bruker this week is show-casing several innovative drug discovery, drug development and process control solutions for small molecule NMR characterization in the pharmaceutical industry.
In recent years, FBDD has emerged as an alternative to traditional high throughput screening. The fragment libraries are characterized by the small size of the compounds and a smaller number of candidate molecules, aiming to identify those that may have initial weak-medium affinities for binding to the desired protein targets, and then optimizing these leads iteratively to obtain medium-strong binding affinities. At each stage, fragment-protein interactions are detected by highly sensitive NMR spectroscopy.
Bruker provides dedicated hard- and software for these FBDD applications: The SampleJet™ high capacity sample changer with cooled sample storage keeps the delicate biomolecular samples from degrading, while at the same time providing maximum throughput. The specifically designed QCI-F CryoProbe™ is a fully versatile, highest sensitivity triple resonance probe with additional fluorine capacity, enabling both, traditional proton- and novel 19F- detected FBDD capabilities. The CMC-q software ensures the integrity and correct concentrations of the fragment libraries. All these latest NMR tools together allow FBDD-by-NMR screens and lead optimization to be performed in a routine and partially automated manner.
“Bruker now offers a suite of innovative NMR pharma tools, designed for next-generation drug discovery approaches and more efficient lead optimization, for increased productivity and for higher quality,” commented Dr. Till Kuehn, Head of Pharma Applications Development for the Bruker BioSpin MRS division. “NMR is a robust, cost-effective, highly quantitative and information-rich analytical tool, and with these new solutions its utility for small molecule pharma applications has been greatly enhanced.”
For over 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics.
For more information on Bruker at ENC 2015, please visit www.bruker.com/enc
Dr. Thorsten Thiel
Director of Marketing Communications
T: +49 (721) 5161–6500
Vice President, Investor Relations
T: +1 (978)-663-3660, ext. 1479